Protein researcher and former Whitehead Institute director Susan Lindquist has died.
In PNAS this week: work toward a CRISPR/Cas9-based approach to treat beta-thalassemia or sickle cell disease, bacteriophages uncovered in human stool, and more.
The study will screen patients using a combination of genotyping and wireless sensors to develop a better diagnostic method.
The firms said their test will be developed to detect levels of the tau protein that can leak into a person's bloodstream after head trauma or injury.
The NIH is seeking grant applications for projects focused on discovering biomarkers in Parkinson's disease and other Parkinsonian syndromes.
IO Informatics has begun beta testing a new iteration of the Sentient software suite with pharma partners ahead of a formal launch planned for the first quarter of 2016.
The test is based on a technology developed by an Amprion co-founder for the amplification of prions.
In two recent deals with 23andMe and Human Longevity, Genentech is planning to sequence thousands of genomes in order to learn more about diseases and inform therapeutic development.
The deal does not cover Voyager's fledgling effort to use RNAi to treat amyotrophic lateral sclerosis.
Using a network-based meta-analysis, a duo from Rosalind Franklin University of Medicine and Science homed in on HNF4A and PTBP1 mRNAs as Parkinson's disease biomarkers.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.